Kiernan T. DeAngelis
Chief Tech/Sci/R&D Officer at Humacyte Global, Inc.
Profile
Kiernan T.
DeAngelis is currently the Chief Medical Officer at Humacyte Global, Inc. Prior to this, he served as the Global Medical Director at AstraZeneca PLC from 2017 to 2019 and as the Senior Medical Director at United Therapeutics Corp.
from 2013 to 2017.
He also previously held the position of Chief Medical Officer at Humacyte, Inc. from 2020 to 2021.
Dr. DeAngelis completed his undergraduate degree at North Carolina State University and obtained his doctorate from Brody School of Medicine.
Kiernan T. DeAngelis active positions
Companies | Position | Start |
---|---|---|
Humacyte Global, Inc.
Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Chief Tech/Sci/R&D Officer | 01/04/2020 |
Former positions of Kiernan T. DeAngelis
Companies | Position | End |
---|---|---|
HUMACYTE, INC. | Chief Tech/Sci/R&D Officer | 01/10/2021 |
ASTRAZENECA PLC | Chief Tech/Sci/R&D Officer | 01/09/2019 |
UNITED THERAPEUTICS CORPORATION | Chief Tech/Sci/R&D Officer | 01/05/2017 |
Training of Kiernan T. DeAngelis
Brody School of Medicine | Doctorate Degree |
North Carolina State University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
HUMACYTE, INC. | Health Technology |
ASTRAZENECA PLC | Health Technology |
UNITED THERAPEUTICS CORPORATION | Health Technology |
Private companies | 1 |
---|---|
Humacyte Global, Inc.
Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Health Technology |
- Stock Market
- Insiders
- Kiernan T. DeAngelis